Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser treatment vs. laser treatment alone in Proliferative Diabetic Retinopathy

Registry ID

EUCTR2011-005542-35

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Novartis Pharma GmbH

Start date

2012-03-27

Completion date

2017-12-05

Last update

2026-08-16

Conditions

• Proliferative diabetic retinopathy

Summary

Change of area of neovascularizations as measured by Fluorescein Angiography at month 12 (difference to baseline value).

Locations

• , , Germany

Related clinical trials

• Evaluation of safety and efficacy of extraocular LED-illumination during vitreoretinal surgery

View on source registry